ArticleInternal medicine journal2026
Guideline concordance of stage IIIA non-small-cell lung cancer treatment in the Australian setting.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStage IIIA non-small-cell lung cancer (NSCLC) is a life-limiting disease, and the level of adherence to evidence-based treatment guidelines in the Australian setting is unclear.
aimTo assess the level of adherence to stage IIIA NSCLC treatment guidelines prior to the advent of immunotherapy and highlight factors that may contribute to guideline non-concordance.
methodsA retrospective cohort study was performed. All patients diagnosed with stage IIIA NSCLC between May 2012 and January 2016 in a Victorian Tertiary Referral Centre were included. Guideline concordant initial treatment (GCIT) was defined according to contemporaneous National Comprehensive Cancer Network (NCCN) recommendations based on tumour resectability. Curative intent treatment was defined as surgery and/or definitive chemoradiotherapy delivered with the aim of disease eradication.
resultsNinety-two patients were included. The mean age of diagnosis was 66 years, and 76.7% had an Eastern Cooperative Oncology Group performance status of 0-1. Curative-intent treatment was delivered in 67.4% of patients, and 62.5% were deemed to have resectable disease of which 58.7% proceeded to surgery. The predominant pre-treatment histological diagnosis was adenocarcinoma (48.3%). Non-operative treatment modalities included platinum-based chemotherapy (64.1%) and radiation (49.4%). One-year survival was 70.5%, while the 5-year survival was significantly lower at 22.2%. Overall, a notable proportion of patients (36.0%) were not treated in accordance with the established guidelines.
conclusionsWhile most patients received GCIT, a significant proportion of patients received no or less intensive treatment. This deviation primarily arose from factors such as advanced age, comorbidities and respiratory impairment at baseline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.